Abstract
Cryogenic magnetoencephalography (MEG) has a lower yield in temporal lobe epilepsy (TLE) than in extra-TLE (ETLE). The advent of optically pumped magnetometers (OPMs) might change this thanks to on-scalp MEG, which allows sensors to be placed closer to the brain and the design of bespoke sensor arrays to target specific brain regions. This study aims to investigate the detection and localization accuracy of interictal epileptiform discharges (IEDs) using on-scalp MEG in TLE and the added-value of face-OPMs for temporal IED detection/localization.
Eleven patients underwent a 1-h MEG recording with OPMs placed both on the scalp (flexible cap, scalp-OPMs) and on the face (3D-printed glass-like structure, face-OPMs). Nine patients also underwent cryogenic MEG. IEDs were visually detected, averaged and localized using distributed source reconstruction. On-scalp MEG IED amplitude and signal-to-noise (SNR) were assessed and compared with cryogenic MEG when more than 10 IEDs were detected. Neural sources with and without face-OPMs were compared. The correlation between face- and scalp-OPMs was assessed.
A mean of 13 IEDs/patient was detected using on-scalp MEG (mean amplitude: 3.3pT, mean SNR: 9.4) and localized in the (medial, anterior, basal, lateral or posterior) temporal lobe. Three patients had >10 IEDs in on-scalp and cryogenic MEG signals with amplitude and SNR that were either higher or similar for the on-scalp MEG recording compared with cryogenic MEG, and sources were separated by 8-11 mm. In two other patients, on-scalp MEG source locations were confirmed by gold-standard methods (surgical resection cavity, n=1; stereo-electroencephalography, n=1). Face-OPMs had a clear added-value (i.e., IED detection and localization) in one patient with antero-medial TLE. Face-OPM signals were correlated with scalp-OPM signals in most patients, showing that face-OPMs recorded brain activity.
This study shows that on-scalp MEG is able to detect and localize IEDs in TLE and to discriminate irritative zones from different key (medial, anterior, basal, lateral or postero-lateral) temporal areas with similar or enhanced SNR than cryogenic MEG. Face-OPMs have a clear added-value in patients with anterior/medial TLE and increase the spatial coverage of the temporal lobe. This study paves the way for the future use of on-scalp MEG in patients with refractory TLE or with other brain disorders affecting the temporal lobe such as, e.g., Alzheimer’s disease.
Competing Interest Statement
N.H. and M.B. hold founding equity in Cerca Magnetics Limited, a spin-off company whose aim is to commercialize aspects of on-scalp MEG technology. The remaining authors have no conflicts of interest.
Funding Statement
O.F. is supported by the Fonds pour la formation a la recherche dans l industrie et l agriculture (FRIA, Fonds de la Recherche Scientifique (FRS-FNRS), Brussels, Belgium). P.C. was supported by the Fonds Erasme (Convention Alzheimer, Brussels, Belgium). P.C. is supported by a research grant of INNOVIRIS (Brussels, Belgium; DetectDem research grant). M.F. is supported by the Fonds Erasme (Convention Alzheimer, Brussels, Belgium). X.D.T. is Clinical Researcher at the FRS-FNRS. The other authors received no additional funding. The on-scalp MEG project at the Hopital Universitaire de Bruxelles and Universite libre de Bruxelles is financially supported by the Fonds Erasme (Projet de Recherche Clinique et Convention Les Voies du Savoir) and by the FRS-FNRS (Credit de Recherche: J.0043.20F, Credit Equipement: U.N013.21F).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was approved by the institutional ethics committee from CUB Hopital Erasme (P2019/426), where the acquisitions were performed.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Few modifications in the introduction.
Data Availability
Data are available upon reasonable request to the corresponding author and after approval by institutional (Hopital universitaire de Bruxelles & Universite libre de Bruxelles) authorities.